In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p<0.001) and doxorubicin (p=0.017), drugs administered during induction therapy. In patients with t(12;21) (n=20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p=0.031; R(2)=0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29.
Lönnerholm
Gudmar
G
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. gudmar.lonnerholm@kbh.uu.se
Thörn
Ingrid
I
Sundström
Christer
C
Frost
Britt-Marie
BM
Abrahamsson
Jonas
J
Behrendtz
Mikael
M
Heldrup
Jesper
J
Jacobsson
Stefan
S
Li
Aihong
A
Olofsson
Tor
T
Porwit
Anna
A
Söderhäll
Stefan
S
Larsson
Rolf
R
Forestier
Erik
E
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D018365:Neoplasm, Residual / Q000175:diagnosis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage
D004317:Doxorubicin; D011239:Prednisolone